Glioblastoma (GBM) Program: ARKA-101 (GLA)

InvestigationalLocal delivery conceptShort-course administration concept
Evidence Summary

What is ARKA-101?

ARKA-101 is an investigational lipid-based approach centered on gamma-linolenic acid (GLA; 18:3 n-6). GLA is a naturally occurring fatty acid that has been studied for its potential effects on tumor cells. Our program is exploring local delivery of GLA directly to the tumor site following surgical resection of glioblastoma.

How it may work

Proposed mechanism of action (based on research observations)

Tumor Cell Vulnerability
Research suggests tumor cells may have altered lipid metabolism that makes them potentially vulnerable to certain lipid-based interventions.
Lipid Peroxidation
Studies have observed lipid peroxidation phenomena in tumor cells exposed to GLA, which may contribute to cellular effects.
Apoptosis Signaling
Research has documented activation of apoptosis (programmed cell death) pathways in laboratory studies.
Local Delivery
Direct administration to the tumor site is being explored to achieve local concentrations while minimizing systemic exposure.

Information presented represents historical observations and preclinical research. Results may not be generalizable and do not predict future clinical outcomes.

Administration Concept

The investigational approach involves local administration via a reservoir placed during standard surgical tumor resection. The concept involves outpatient daily dosing for approximately 7-10 days, allowing patients to return home between administrations.

Day 0

Surgery + Reservoir Placement

Days 1-10

Daily Local Administration

Follow-up

Monitoring + Standard Care

Evidence Summary

FAQs for Patients & Caregivers

Common questions about our investigational program

Important Notice: ARKA-101 is investigational and not approved by the FDA or any regulatory authority. It is not available as an approved treatment option.

Want to learn more?

Request our information deck or connect with our team to discuss the GBM program.